Most Recent Articles about SNY
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics http://www.zacks.com/stock/news/373225/regeneron-alnylam-extend-collaboration-for-rnai-therapeutics?cid=CS-ZC-FT-373225 Apr 09, 2019 - Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes http://www.zacks.com/stock/news/366338/astrazenecas-forxiga-gets-nod-in-japan-for-type-i-diabetes?cid=CS-ZC-FT-366338 Mar 28, 2019 - AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
Lilly (LLY) Signs New Immunology Deal With Private Biotech http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-ZC-FT-365638 Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

Related Companies

Name Exchange Price Mkt Cap
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
ABT Abbott Laboratories NYSE $67.67 $118.71B
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
Sector: Health Care > Industry: Major Pharmaceuticals